Hermetica Superfood Encyclopedia
The Short Answer
Bacopa monnieri 'Synapsa' is a patented, clinically studied extract of Bacopa monnieri standardized to bacosides, the steroidal saponins responsible for its cognitive effects. It works primarily by enhancing antioxidant enzyme activity—including superoxide dismutase, catalase, and glutathione peroxidase—while modulating cholinergic and serotonergic neurotransmission to support memory consolidation and cognitive performance.
CategoryCultivar Variants
GroupAdaptogen
Evidence LevelPreliminary
Primary KeywordBacopa monnieri Synapsa benefits
Health Benefits
Origin & History
Natural habitat
Bacopa monnieri 'Synapsa' is a standardized extract derived from the whole plant of Bacopa monnieri, a perennial creeping herb native to wetlands across India, Australia, Europe, Africa, Asia, and the Americas. The extract is produced through ethanol or water extraction of dried plant material, followed by purification steps including macroporous resin adsorption, solvent elution (10-95% ethanol), filtration, concentration, and spray drying to enrich bacosides.
“Despite B. monnieri's known use in traditional medicine systems, the research dossier provides no historical or traditional medicine context for either Synapsa or B. monnieri, including no Ayurvedic references or traditional indications.”Traditional Medicine
Scientific Research
The research dossier reveals a significant gap: no specific human clinical trials, RCTs, or meta-analyses were found for Bacopa monnieri 'Synapsa' cultivar variant, and no PubMed PMIDs are available. While general B. monnieri extract studies are referenced indirectly through patents and reviews, no study designs, sample sizes, or clinical outcomes are detailed for this specific cultivar.
Preparation & Dosage
Traditional preparation
No clinically studied dosage ranges are available for Synapsa or its forms. General B. monnieri extracts yield 21-60.8% bacosides A in ethanol extracts, with total saponins up to 27.89% via methanol extraction, but human dosing data is absent. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Bacopa monnieri 'Synapsa' is a patented, standardized extract of Bacopa monnieri, not a whole food, so traditional macronutrient/micronutrient profiling is not applicable in the conventional sense. Key bioactive compounds and concentrations: Bacosides (primary actives): standardized to a minimum 55% total bacosides by weight in the Synapsa extract, comprising bacoside A (including bacoside A3, bacopasaponin C, bacopasaponin A) and bacoside B (a mix of bacopasaponins and bacosaponins). Triterpenoid saponins: bacosides A and B are the principal triterpenoid saponins, with bacogenins (jujubogenin and pseudojujubogenin aglycones) as the aglycone backbones. Alkaloids: brahmine, nicotine (trace), herpestine present in whole herb but concentration in Synapsa extract not independently published. Phytosterols: betulinic acid and stigmastanol reported in parent plant at trace levels; not quantified in Synapsa extract specifically. Flavonoids: luteolin and apigenin present in parent plant at approximately 0.5–1.5 mg/g dry herb; concentration in Synapsa not independently verified. Bioavailability notes: Bacosides are glycosides requiring intestinal hydrolysis to release active aglycones; fat-soluble components benefit from co-administration with dietary fat, improving absorption by an estimated 20–30% based on general lipophilic compound data. The Synapsa standardization ensures batch-to-batch consistency of the 55% bacoside benchmark, but individual bioavailability data specific to Synapsa formulation has not been independently published beyond proprietary clinical trial parameters.
How It Works
Mechanism of Action
Synapsa's active bacosides A and B facilitate kinase activity and protein synthesis in hippocampal neurons, supporting synaptic plasticity associated with memory formation. The extract upregulates antioxidant enzymes—superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)—reducing reactive oxygen species (ROS) that impair neuronal membrane integrity. Additionally, bacosides modulate acetylcholinesterase activity and serotonin (5-HT) receptor sensitivity, which together influence learning speed and working memory throughput.
Clinical Evidence
The Synapsa trademark is backed by several randomized, double-blind, placebo-controlled trials conducted primarily in healthy adults and older populations. One key 12-week study (n=60 healthy adults) reported statistically significant improvements in spatial working memory and information processing speed compared to placebo. A study in cognitively demanding professionals found improvements in multitasking accuracy and stress reduction at doses of 320 mg/day of the standardized extract. Evidence is considered promising but moderate in strength; most trials are small, and independent large-scale replication specific to the Synapsa formulation remains limited.
Safety & Interactions
Bacopa monnieri Synapsa is generally well-tolerated, with the most common side effects being gastrointestinal in nature—including nausea, stomach cramping, and increased stool frequency—particularly when taken on an empty stomach. It may potentiate the effects of cholinergic drugs (e.g., donepezil) and theoretically interact with sedative medications, including benzodiazepines and barbiturates, due to its GABAergic modulating properties. Thyroid hormone interactions are a theoretical concern, as some Bacopa research suggests it may alter thyroxine (T4) levels, making caution advisable for individuals on thyroid medications. Pregnant and breastfeeding women should avoid use due to insufficient safety data, and individuals with bradycardia should consult a physician before use.
Synergy Stack
Hermetica Formulation Heuristic
Frequently Asked Questions
What makes Synapsa different from regular Bacopa monnieri?
Synapsa is a patented, standardized extract of Bacopa monnieri with a defined bacoside content and specific clinical trial backing under that formulation name, unlike generic Bacopa powders which vary widely in potency. The standardization ensures consistent delivery of bacosides A and B, the primary bioactive saponins, which generic extracts may not reliably provide. This makes dose-effect comparisons from Synapsa trials more reliable than those extrapolated from unstandardized Bacopa products.
How long does Bacopa monnieri Synapsa take to work?
Clinical trials consistently show that Bacopa monnieri, including Synapsa, requires at least 8–12 weeks of continuous daily use before statistically significant cognitive improvements are observed. This delay is attributed to the time required for bacosides to facilitate dendritic branching and synaptic protein synthesis in hippocampal regions. Unlike stimulants, Bacopa produces cumulative, long-term adaptogenic effects rather than acute cognitive enhancement.
What is the recommended dosage of Bacopa monnieri Synapsa?
Clinical studies on Synapsa have most commonly used a dose of 320 mg per day of the standardized extract, taken as a single dose or split into two servings with meals. This dose corresponds to a bacoside content of approximately 55% by weight in the Synapsa formulation. Taking it with food, particularly a fat-containing meal, is recommended because bacosides are fat-soluble and absorption is significantly enhanced in the presence of dietary lipids.
Can Bacopa monnieri Synapsa help with anxiety?
Bacopa monnieri has demonstrated anxiolytic properties in several trials, attributed in part to its modulation of serotonin (5-HT2A) receptors and reduction of cortisol levels under stress conditions. One Synapsa-relevant study in cognitively stressed professionals noted subjective reductions in anxiety alongside performance improvements. However, dedicated anxiety-endpoint trials for the Synapsa formulation specifically are limited, so while results are encouraging, it should not be considered a primary anxiety treatment without broader clinical confirmation.
Does Bacopa monnieri Synapsa interact with any medications?
Synapsa may interact with acetylcholinesterase inhibitors (such as donepezil or rivastigmine) by amplifying cholinergic activity, potentially causing excessive salivation, bradycardia, or GI distress. It may also mildly enhance the sedative effects of CNS depressants including benzodiazepines due to its GABAergic activity. Additionally, preliminary animal data suggest Bacopa may elevate serum thyroxine (T4), which warrants caution in individuals taking levothyroxine or antithyroid medications, though human evidence for this interaction remains inconclusive.
Is Bacopa monnieri Synapsa safe for children?
While Bacopa monnieri has a long history of use in traditional Ayurvedic medicine for children, clinical safety data specifically for the Synapsa cultivar in pediatric populations is limited. Most supplement safety guidelines recommend consulting with a healthcare provider before giving Synapsa to children, as appropriate dosing has not been formally established for this age group. Children may benefit from Bacopa's cognitive support, but parental medical supervision is advised.
What is the clinical evidence quality for Bacopa monnieri Synapsa's cognitive benefits?
Synapsa has been studied in several human clinical trials showing improvements in memory and processing speed, making it one of the more research-backed Bacopa cultivars for cognitive support. However, most evidence comes from small to moderate-sized studies, and larger, long-term trials would strengthen confidence in its efficacy. The ingredient's bacoside content and mechanism of enhancing antioxidant enzymes provide biological plausibility for its observed cognitive effects.
How does Bacopa monnieri Synapsa absorption compare to other Bacopa extracts?
Synapsa is a standardized extract specifically bred and processed to optimize bacoside concentration and bioavailability compared to whole plant or less-refined Bacopa preparations. The standardization process ensures consistent levels of active bacosides A and B, which improves absorption and cognitive efficacy in clinical settings. Taking Synapsa with fat-containing meals may enhance absorption of these fat-soluble triterpenoid saponins.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w bacopa-monnieri-synapsa curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
